INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
04/19/2026
Back to search
Official data from USPTO
STAT-X
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
04/20/2026
Trademark type
Combined
Nice classes
5
Filing date
05/20/2022
Registration date
07/18/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/18/2023
Last transaction
04/20/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
CN
Examiner
AGREDA, SAMANTHA LEIGH
Current location
Historical data usage
Mark description
The mark consists of the stylized wording "STAT-X" where the letter "A" forms a cardiography wave that underlines the remaining letters.
Holders and representatives
Holders
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
Representatives
Stacy L. Emhoff Walker & Jocke Co., LPA
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationspharmaceutical preparations for the functional analysis of blood coagulation and fibrinolysis; Pharmaceutical preparations for the quantitative and qualitative detection of substances in human serumplasma and body fluids; Chemico-pharmaceutical preparations for pharmaceutical purposeschemico-pharmaceutical preparations for pharmaceutical purposes for the functional analysis of blood coagulation and fibrinolysis; Chemico-pharmaceutical preparations for pharmaceutical purposes for the quantitative and qualitative detection of substances in human serumplasma and body fluids; Medicated serums used for the functional analysis of blood coagulation and fibrinolysis; Medicated serums used for the quantitative and qualitative detection of analytes in human serumplasma and body fluids; Medicines for serum therapymedicines for serum therapy for functional analysis of blood coagulation and fibrinolysis; Medicines for serum therapy for the quantitative and qualitative detection of substances in human serumplasma and body fluids; Biological preparations for medical purposesbiological preparations for medical purposes for the functional analysis of blood coagulation and fibrinolysis; Biological preparations for medical purposes for the quantitative and qualitative detection of substances in human serumplasma and body fluids; Chemical preparations for pharmaceutical purposeschemical preparations for pharmaceutical purposes for the functional analysis of blood coagulation and fibrinolysis; Chemical preparations for pharmaceutical purposes for the quantitative and qualitative detection of substances in human serumplasma and body fluids; chemical preparations for medical purposeschemical preparations for medical purposes for the functional analysis of blood coagulation and fibrinolysis; chemical preparations for medical purposes for the quantitative and qualitative detection of substances in human serumplasma and body fluids; enzymes for medical purposes; enzyme preparations for medical purposes; Preparations for pharmaceutical purposespreparations for pharmaceutical purposes made of trace elements that are found in the human body for the functional analysis of blood coagulation and fibrinolysis; Preparations for pharmaceutical purposes made of trace elements that are found in the human body for the quantitative and qualitative detection of substances in human serumplasma and body fluids; amino acids for medical purposes; preparations of microorganisms for medical or veterinary use; chemical preparations for the diagnosis of pregnancy; diagnostic preparations for medical purposes; reagent paper for medical purposes; diagnostic biomarker reagents for medical purposes; veterinary preparations for treatment of intestinal bacteria; medicines for veterinary purposes for treatment of intestinal bacteria; biological preparations for veterinary purposes for treatment of intestinal bacteria; chemical preparations for veterinary purposes for treatment of intestinal bacteria; enzymes for veterinary purposes; enzyme preparations for veterinary purposes; diagnostic preparations for veterinary purposes ; reagent paper for veterinary purposes
Publications
History of USPTO decisions and trademark events.
30 publications found
NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
08/26/2025
A7OK
AMENDMENT UNDER SECTION 7 - PROCESSED
08/06/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/05/2025
ES7R
TEAS SECTION 7 REQUEST RECEIVED
01/16/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/19/2023
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
10/19/2023
XXCR
GENERIC MADRID TRANSACTION CREATED
10/19/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/18/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/18/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
07/18/2023
GPNX
NOTIFICATION PROCESSED BY IB
05/02/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/02/2023
PUBO
PUBLISHED FOR OPPOSITION
05/02/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/12/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/12/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/12/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/30/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/30/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/30/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/30/2023
RFNP
REFUSAL PROCESSED BY IB
01/05/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/09/2022
RFRR
REFUSAL PROCESSED BY MPU
12/08/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/28/2022
CNRT
NON-FINAL ACTION WRITTEN
09/27/2022
DOCK
ASSIGNED TO EXAMINER
09/21/2022
MAFR
APPLICATION FILING RECEIPT MAILED
07/19/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/15/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/14/2022
Continuous trademark protection
Get notified about every new filing that threatens STAT-X or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.